In a significant leadership transition for the sleep medicine community, the Narcolepsy Network—a premier national nonprofit dedicated to individuals navigating the complexities of narcolepsy and idiopathic hypersomnia (IH)—has officially appointed Liz Burgess as its new executive director. The appointment marks a strategic pivot for the organization, which is currently celebrating its 40th anniversary and operating within an increasingly fast-paced landscape of medical innovation.
With over two decades of executive nonprofit experience, Burgess arrives at a time when the patient advocacy group is looking to bridge the gap between clinical advancements and the lived, daily realities of those it serves.
The Appointment: Bridging Professional Expertise and Lived Experience
Liz Burgess brings a dual-layered background to the Narcolepsy Network that is increasingly sought after in the rare disease space. Her resume is defined by more than 20 years of mission-driven leadership, most recently demonstrated by her successful tenure as the leader of the Bleeding Disorders Alliance Illinois. During her time there, she was instrumental in revitalizing the organization’s operational framework, honing a skillset that spans fiscal sustainability, strategic fundraising, and the navigation of complex pharmaceutical partnerships.
However, it is her personal history that has resonated most strongly with the board and the membership. As an adult diagnosed with epilepsy, Burgess understands the unique psychological and physical toll of a chronic, life-altering condition. This firsthand experience allows her to speak the language of the patient while maintaining the professional rigor required to lead a national organization.
"I know from my own journey that you don’t just join an organization like Narcolepsy Network for information—you join to find ‘your people’ and a community that truly understands your daily reality," Burgess said in an official statement. "My immediate priority is to immerse myself in the Narcolepsy Network community and listen. I am looking forward to meeting our members and their families, hearing their stories, and ensuring they feel supported through every phase of their lives."
Chronology: The Road to New Leadership
The search for a new executive director was not a hasty process; rather, it was a data-driven initiative designed to reflect the evolving needs of the narcolepsy community.
Earlier this year, the Narcolepsy Network board initiated a comprehensive outreach effort, distributing a survey to more than 125 members. The goal was to identify the specific qualities that patients and their families valued most in their leadership. The feedback was clear: the membership was seeking a "holistic" leader. They desired someone who viewed narcolepsy and IH not merely as medical conditions to be managed by medication, but as life-altering, daily struggles that require a multi-dimensional support system.
The findings from this survey served as the blueprint for the executive search. The board prioritized candidates who could demonstrate a balance between "nonprofit management" and "collaborative spirit."
Following the vetting process, the appointment of Burgess was announced to coincide with the organization’s 40th anniversary. This timing is symbolic; as the organization looks back on four decades of advocacy, it is also positioning itself for a future that looks vastly different from its origins in 1984.
Supporting Data: Why Leadership Matters in the Rare Disease Space
The importance of this appointment cannot be overstated when considering the current state of the sleep medicine field. For years, the patient community has relied on Narcolepsy Network for education and advocacy, but the "landscape" of the disease is currently undergoing its most significant shift in decades.
Industry researchers are currently engaged in a high-stakes "race" toward the development of orexin agonists. Type 1 narcolepsy is characterized by the loss of orexin (hypocretin), a brain chemical critical for regulating wakefulness. For most of the past 40 years, treatments for narcolepsy have focused solely on symptom management—using stimulants or sedative agents to help patients stay awake or sleep more soundly.
However, the current pipeline of therapies under clinical trials and FDA review seeks to address the root cause of the condition rather than the symptoms. As these therapies move from the lab to the clinic, the role of an advocacy group like the Narcolepsy Network becomes more complex. They must now serve as a bridge between high-level clinical research and the patient population, ensuring that members are informed, empowered, and protected as new pharmaceutical options enter the market.
Official Responses: A Mandate for Empathy and Acumen
The board’s decision to appoint Burgess was met with high confidence from leadership. Keith Harper, the president of the board for Narcolepsy Network, emphasized that Burgess was chosen because she possessed a rare "alignment" of skills.
"Liz perfectly aligns with the high standards we set for our next leader, as well as community priorities," Harper stated. "She brings the strategic acumen required to advance our mission, while possessing the personal passion and empathy to keep us anchored in the specific needs of the narcolepsy and IH community."
Harper highlighted that as the community faces a wave of new clinical developments, the need for a steady, compassionate hand is paramount. "We are incredibly fortunate to have Liz’s leadership at this pivotal time, as our community continues to rely on Narcolepsy Network for support and education to navigate the evolving landscape," he added.
Implications: The Future of the Narcolepsy Network
What does this leadership change mean for the average person living with narcolepsy? The implications are three-fold:
1. A Shift Toward Holistic Advocacy
By hiring a leader who explicitly prioritizes the "holistic daily struggle," the organization is signaling a departure from purely clinical or academic advocacy. Under Burgess, members can expect an increased focus on quality-of-life initiatives—mental health resources, social support, and programs that address the employment and educational disparities often faced by those with sleep disorders.
2. Strategic Navigation of Clinical Innovation
With major pharmaceutical breakthroughs on the horizon, the Narcolepsy Network will likely play a more active role in clinical trial advocacy and patient education regarding new drugs. Burgess’s experience in the bleeding disorders space, where pharmaceutical partnerships are highly complex, suggests she will be well-equipped to manage these relationships without compromising the organization’s primary mission: the patient’s best interest.
3. Community-Centric Operations
The "listening tour" that Burgess mentioned in her opening statement is more than just a public relations gesture; it is a management philosophy. By making herself accessible to families and members, she is attempting to re-center the organization’s hierarchy. Instead of a top-down approach, the Narcolepsy Network is positioning itself to be a bottom-up organization, guided by the lived experiences of those it represents.
Conclusion: A New Era
As the Narcolepsy Network celebrates its 40th year, it finds itself at a unique intersection. It has the weight of history behind it, a renewed sense of purpose from its membership, and now, a new executive director with the exact combination of professional experience and personal empathy required to navigate the road ahead.
For a community that has historically felt misunderstood or marginalized by the medical establishment, the appointment of Liz Burgess is a promising step forward. As the organization moves into its next decade, the focus remains clear: to ensure that while researchers work on the cure, the patients have a network that ensures they are not walking the path alone. Whether through the advocacy for better access to care or the simple, human connection of finding "your people," the Narcolepsy Network appears poised to remain a vital pillar of the rare disease community under its new leadership.
